Uses of pyrimidopyrimidinones as SIK inhibitors

US11878019B2 · kind B2 · utility

Assignees

• The General Hospital Corporation · US
• DANA-FARBER CANCER INSTITUTE, INC. · US

Inventors

• David E. Fisher · Newton, US
• Nisma Mujahid · Spencerport, US
• Ryo Murakami · Tokyo, JP
• Nathanael S. Gray · Boston, US
• Yanke Liang · Belmont, US
• Hwan Geun Choi · Seoul, KR

Key dates

• Filing date: Nov 22, 2021
• Grant date: Jan 23, 2024
• Expiry date: Jan 11, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides methods of increasing skin pigmentation in a subject in need thereof using salt-inducible kinase (SIK) inhibitors, such as macrocyclic compounds of Formula (I), bicyclic urea compounds of Formula (II), (III), and (IV), and compounds of Formula (V), (VI), (VI-A), or (VII). Also provided are pharmaceutical compositions, methods, and uses that include or involve a compound described herein.